Professor Mark Kendall is a Biomedical Engineer and innovator with more than 16 years of experience researching the field of needle-free gene and drug delivery to skin (authoring > 200 papers). Mark is an inventor of more than 100 patents – and has worked closely with industrial partners, from concept to commercialisation. First, he helped the Biolistics technology be successfully commercialised, with PowderMed purchased by Pfizer for $400 million in 2006. Mark joined the University of Queensland in 2006 for a Professorial position after 8 years at the University of Oxford, where he was Associate Director of the PowderJect Centre for Gene and Drug Delivery Research, a University Research Lecturer and College Lecturer (Magdalen College). He co-founded Vaxxas, with $15 million of investment to commercialize the Nanopatch. Awards include being a 2012 Rolex Laureate for Enterprise; The Winner of the Australian Innovation Challenge 2011; Australia Museum Eureka Prize 2011; Younger Engineer of Britain 2004.